Clorox Beats Adjusted EPS but Revenue Misses; Shares Slide 6.4% After Hours

Earnings Snapshot

- Adjusted EPS: $1.64 (beat by $0.07)

- GAAP EPS: $1.54 (missed consensus)

- Revenue: $2.0 B vs. $1.67 B estimate (miss)

- Gross margin: 43.2% (down 140 bps)

- YoY sales: flat at $1.67 B (organic sales down 1%)

Clorox’s third‑quarter results were a mixed bag. While the company delivered a solid adjusted EPS beat, top‑line growth stalled, leaving revenue shy of analyst expectations. The margin compression reflected higher manufacturing and logistics costs and an unfavorable product mix, partially offset by cost‑saving initiatives.

Guidance and Outlook

During the earnings call, CEO Linda Rendle reiterated the company’s full‑year outlook but signaled a modest downgrade. According to a Wall Street Journal report released shortly after the filing, Clorox cut its FY2026 adjusted EPS guidance, citing the transaction costs tied to the April 1 acquisition of GOJO Industries (Purell) and ongoing investments in digital capabilities. The revised outlook now projects adjusted EPS of $6.30‑$6.45, down from the prior $6.55‑$6.70 range.

Conference Call Highlights

- Acquisition integration: Management highlighted early traction for the Purell brand, noting “velocities exceeding expectations.” However, integration costs are expected to weigh on near‑term earnings.

- Cost discipline: The company pointed to $150 M in cost savings from advertising and SG&A reductions, which helped offset higher logistics expenses.

- Segment performance: Household sales rose 3% on volume, while Lifestyle fell 9% on weaker demand. International sales grew 8% on favorable FX and volume.

- Cash flow: Net cash from operations fell 59% YoY to $282 M, primarily due to a termination payment on the Glad joint‑venture agreement.

Market Reaction

The earnings beat on adjusted EPS was not enough to offset the revenue miss and guidance cut. In after‑hours trading, CLX fell 6.43% to $90.23, down from $96.44 at the prior close. Analysts on Bloomberg and TipRanks quickly trimmed price targets, with the consensus moving from $102 to $96, reflecting concerns over margin pressure and the cost of integrating GOJO.

Analyst Commentary

- Morgan Stanley: “The adjusted EPS beat is encouraging, but the revenue shortfall and lowered FY guidance suggest the cost tailwinds from the GOJO deal will linger.”

- Barclays: “We downgrade CLX to ‘Neutral’ and cut the 12‑month price target to $95, citing weaker-than‑expected top‑line momentum and a slower market‑share recovery in core cleaning categories.”

What’s Next?

Clorox will focus on accelerating market‑share gains in its health‑and‑wellness portfolio while continuing to drive cost efficiencies. The company expects the Purell integration to start delivering incremental profit contribution in FY2027. Investors will be watching the upcoming Q4 earnings for signs that the cost curve is flattening and that the newly‑added GOJO assets are beginning to offset the integration expense.

---

The article reflects data from the SEC 8‑K filing, the company press release, and post‑earnings market commentary from MarketBeat, PRNewswire, the Wall Street Journal, TipRanks, and analyst notes.